DBV Technologies reported -23039000 in Net Income for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
DBV Technologies DBVT:US -23039000 6.33M
Acadia Pharmaceuticals ACAD:US $ -34.01M 79.04M
Alnylam Pharmaceuticals ALNY:US $ -277.4M 37.06M
Amarin AMRN:US $ -69.96M 38.39M
Biocryst Pharmaceuticals BCRX:US $ -58.86M 15.34M
Biomarin Pharmaceutical BMRN:US $ 27.66M 93.13M
Eleven Biotherapeutics EBIO:US $ -0.81M 9.75M
Esperion Therapeutics ESPR:US $ -66324000 9.59M
Halozyme Therapeutics HALO:US $ 22.68M 37.42M
Insmed INSM:US $ -95645000 1.02M
Intercept Pharmaceuticals ICPT:US $ -7.53M 9.76M
IONIS PHARMACEUT IONS:US $ -105.14M 39.97M
Neurocrine Biosciences NBIX:US $ -16.9M 30.8M
Ptc Therapeutics PTCT:US $ -152.09M 25.36M
Sarepta Therapeutics SRPT:US $ -231.48M 126.46M
Ultragenyx Pharmaceutical RARE:US $ -158.16M 5.84M
United Therapeutics UTHR:US $ 116M 123.9M
YTE INCY:US $ 161.43M 123.44M